WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 401430
Description: Droxinostat, also known as NS 41080, is a selective inhibitor of HDAC3, HDAC6, and HDAC8. Droxinostat shows comparable inhibition of HDAC6 and HDAC8 (IC50 = 2.47 and 1.46 μmol/L, respectively).
MedKoo Cat#: 401430
Chemical Formula: C11H14ClNO3
Exact Mass: 243.06622
Molecular Weight: 243.68676
Elemental Analysis: C, 54.22; H, 5.79; Cl, 14.55; N, 5.75; O, 19.70
Synonym: NS 41080; NS41080; NS-41080; Droxinostat;
IUPAC/Chemical Name: 4-(4-chloro-2-methylphenoxy)-N-hydroxybutanamide
InChi Key: JHSXDAWGLCZYSM-UHFFFAOYSA-N
InChi Code: InChI=1S/C11H14ClNO3/c1-8-7-9(12)4-5-10(8)16-6-2-3-11(14)13-15/h4-5,7,15H,2-3,6H2,1H3,(H,13,14)
SMILES Code: O=C(NO)CCCOC1=CC=C(Cl)C=C1C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 243.68676 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Bijangi-Vishehsaraei K, Saadatzadeh MR, Huang S, Murphy MP, Safa AR. 4-(4-Chloro-2-methylphenoxy)-N-hydroxybutanamide (CMH) targets mRNA of the c-FLIP variants and induces apoptosis in MCF-7 human breast cancer cells. Mol Cell Biochem. 2010 Sep;342(1-2):133-42. Epub 2010 May 6. PubMed PMID: 20446019.
2: Wood TE, Dalili S, Simpson CD, Sukhai MA, Hurren R, Anyiwe K, Mao X, Suarez Saiz F, Gronda M, Eberhard Y, MacLean N, Ketela T, Reed JC, Moffat J, Minden MD, Batey RA, Schimmer AD. Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther. 2010 Jan;9(1):246-56. Epub 2010 Jan 6. PubMed PMID: 20053768.
Droxinostat has shown a potent action against HDAC3, HDAC6, and HDAC8 which are pyrimidyl-hydroxamic acid-dependent histone deacetylases. Chemically Droxinostat stands for 4-(4-chloro-2-methylphenoxy)-N-hydroxybutanamide. It contains a hydroxamic acid moiety. Caspase 8 is an effective stimulator of apoptosis and its action is inhibited by the protein FLIP. Hence FLIP inhibits apoptosis and Droxinostat targets FLIP induced inhibition of apoptosis.
Droxinostat shows a significant action on gene transcription hence controlling tumor progression. The cells resistant to the caspase mediated apoptotic pathway get sensitized by Droxinostat, hence proving an active agent of introducing death in cancerous cells. (source: http://www.hdacblog.com/2011/10/droxinostat-active-inhibitor-of-hdac3.html).